 |
|
|
|
 |
|
|
| Article 1 to 10 out of 8760
|
09 Feb 2010
-
Method of the future uses single-cell imaging to identify gene interactions
(09 Feb 2010)
Cellular imaging offers a wealth of data about how cells respond to stimuli, but harnessing this technique to study biological systems is a daunting challenge. In a study published in Genome Research, researchers have developed a novel method ...
-
A potent suppressor of endometrial cancer is revealed
(09 Feb 2010)
Researchers define genetic changes that cause widespread malignant growth of cells lining the uterus
Endometrial cancer is the most common cancer of the female reproductive tract, representing 6% of all cancers. There is currently no screening method or biomarker to indicate early presence of disease. "It is a very common malignancy that ...
-
Inhibiting serotonin in gut could cure osteoporosis
(09 Feb 2010)
An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in ...
-
Virus-free technique enables Stanford scientists to easily make stem cells pluripotent
(09 Feb 2010)
Tiny circles of DNA are the key to a new and easier way to transform stem cells from human fat into induced pluripotent stem cells for use in regenerative medicine, say scientists at the Stanford University School of Medicine. Unlike other ...
-
Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
(09 Feb 2010)
Addex Pharmaceuticals announced that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)-induced reductions in ...
-
Molecular 'firing squad' in mice triggered by overeating destroys metabolism
(09 Feb 2010)
Overeating in mice triggers a molecule once considered to be only involved in detecting and fighting viruses to also destroy normal metabolism, leading to insulin resistance and setting the stage for diabetes. The new study, led by researchers ...
-
Paloma Pharmaceuticals Receives Approval to Enter Phase I Clinical Trials
(09 Feb 2010)
IND Accepted by FDA to Initiate Intravitreal and Subconjunctival Administration of Palomid 529 in Age-Related Macular Degeneration Patients -
Paloma Pharmaceuticals, Inc. announced that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to ...
-
Promising Proof-of-Concept study results to be reported for PNB01 in Major Depression
(09 Feb 2010)
Pharmaneuroboost (PNB) reported that the results of it’s phase II Proof-of-Concept study with PNB01 in Major Depression will be presented at the 18th European Congress of Psychiatry on March 2nd in Munich. "The results are impressive and ...
-
Sorbus Pharmaceuticals GmbH incorporated in Vienna, Austria
(09 Feb 2010)
Sorbus Pharmaceuticals GmbH announced its incorporation in Vienna, Austria. Sorbus discovers and develops novel treatments for complicated wounds, cancer and other life-threatening diseases. Its lead drug, SertaSil, has demonstrated exceptional ...
-
BASF and Embrapa’s Cultivance soybeans receive approval for commercial cultivation in Brazil
(09 Feb 2010)
First genetically modified crop developed in Brazil to reach commercialization stage
Embrapa, the Brazilian Agricultural Research Cooperation, and BASF’s jointly developed herbicide-tolerant soybeans were green-lighted by CTNBio. CTNBio, the Brazilian Biosafety Technical Commission stated that the genetically modified soybeans ...
|
|
|
|
|
Top
